[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO2573121T3 - - Google Patents

Info

Publication number
NO2573121T3
NO2573121T3 NO12006790A NO12006790A NO2573121T3 NO 2573121 T3 NO2573121 T3 NO 2573121T3 NO 12006790 A NO12006790 A NO 12006790A NO 12006790 A NO12006790 A NO 12006790A NO 2573121 T3 NO2573121 T3 NO 2573121T3
Authority
NO
Norway
Application number
NO12006790A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39313041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2573121(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2573121T3 publication Critical patent/NO2573121T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO12006790A 2007-10-15 2008-10-14 NO2573121T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07291259A EP2050764A1 (de) 2007-10-15 2007-10-15 Neues polyvalentes bispezifisches Antikörperformat und Verwendung
US3712808P 2008-03-17 2008-03-17
EP08839958.9A EP2205640B1 (de) 2007-10-15 2008-10-14 An il-4 und/oder il-13 bindende antikörper und ihre anwendung
EP12006790.5A EP2573121B1 (de) 2007-10-15 2008-10-14 Antikörper, die IL-4 und/oder IL-13 binden, und ihre Verwendung

Publications (1)

Publication Number Publication Date
NO2573121T3 true NO2573121T3 (de) 2018-01-20

Family

ID=39313041

Family Applications (2)

Application Number Title Priority Date Filing Date
NO12006790A NO2573121T3 (de) 2007-10-15 2008-10-14
NO12006789A NO2574629T3 (de) 2007-10-15 2008-10-14

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO12006789A NO2574629T3 (de) 2007-10-15 2008-10-14

Country Status (43)

Country Link
US (17) US8388965B2 (de)
EP (12) EP2050764A1 (de)
JP (5) JP5858616B2 (de)
KR (5) KR101681909B1 (de)
CN (3) CN113480647A (de)
AR (3) AR068861A1 (de)
AU (5) AU2008312655B2 (de)
BR (1) BRPI0818677B8 (de)
CA (3) CA3071750C (de)
CL (4) CL2008003037A1 (de)
CR (5) CR11337A (de)
CY (5) CY1114987T1 (de)
DK (5) DK2573121T3 (de)
DO (3) DOP2010000109A (de)
ES (5) ES2660152T3 (de)
GT (1) GT201000067A (de)
HN (1) HN2010000710A (de)
HR (5) HRP20140150T1 (de)
HU (4) HUE037205T2 (de)
IL (2) IL205005A (de)
LT (4) LT2574630T (de)
MA (1) MA31838B1 (de)
MX (6) MX363638B (de)
MY (1) MY171214A (de)
NI (7) NI201000402A (de)
NO (2) NO2573121T3 (de)
NZ (3) NZ709353A (de)
PA (1) PA8799001A1 (de)
PE (1) PE20091382A1 (de)
PH (2) PH12013501032A1 (de)
PL (5) PL2573119T3 (de)
PT (5) PT2205640E (de)
RS (5) RS57396B1 (de)
RU (4) RU2580049C2 (de)
SG (4) SG185303A1 (de)
SI (5) SI2573121T1 (de)
TN (1) TN2010000126A1 (de)
TR (2) TR201810005T4 (de)
TW (4) TWI616205B (de)
UA (2) UA118949C2 (de)
UY (1) UY31394A1 (de)
WO (1) WO2009052081A2 (de)
ZA (1) ZA201002069B (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
EP2050764A1 (de) * 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
BRPI0819693A2 (pt) * 2007-11-30 2020-08-18 Glaxo Group Limited Construção de ligação de antígeno, método para tratar um paciente que sofre de câncer ou uma doença inflamatória, sequência de polinucleotídeo, polinucleotídeo, célula hospedeira transformada ou transfectada recombinante, método para produziruma construção de ligação de antígeno, e, composição farmacêutica
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
AU2009282234A1 (en) * 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
ES2667258T3 (es) * 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
EP2478013B1 (de) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled-coil- und/oder tether-haltige proteinkomplexe und verwendungen davon
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
EP2596114A4 (de) * 2010-07-14 2014-01-08 Amgen Inc Domäneneinsatz-immunoglobulin
EP2601298B1 (de) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Maüse, die vl domäne enthaltende bindende proteine machen
EP3252072A3 (de) 2010-08-03 2018-03-14 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne und verwendungen davon
EP2609112B1 (de) 2010-08-24 2017-11-22 Roche Glycart AG Aktivierbare bispezifische antikörper
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
PT3199547T (pt) * 2011-03-28 2021-02-02 Sanofi Sa Proteínas de ligação semelhantes a anticorpos de região variável dupla possuindo orientação cruzada da região de ligação
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2710042A2 (de) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multispezifische fab-fusionsproteine und verwendungsverfahren dafür
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
DK3865581T3 (da) 2011-08-05 2024-10-21 Regeneron Pharma Humaniserede, universelle letkædemus
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
ES2812564T3 (es) 2011-11-23 2021-03-17 Bioven 3 Ltd Proteínas recombinantes y sus usos terapéuticos
WO2013103783A1 (en) * 2012-01-04 2013-07-11 Sanofi Us Murine il-13 antibodies
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
SG10201702842SA (en) * 2012-03-27 2017-06-29 Genentech Inc Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
BR112014032193A2 (pt) 2012-06-27 2017-06-27 Hoffmann La Roche métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
JP6309002B2 (ja) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
CN104755495A (zh) 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
HRP20230623T1 (hr) 2012-09-12 2023-09-29 Genzyme Corporation Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom
CA2889488A1 (en) 2012-11-01 2014-05-08 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
MX2015005593A (es) 2012-11-01 2016-02-05 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas.
CA2889962C (en) 2012-11-20 2023-10-24 Sanofi Anti-ceacam5 antibodies and uses thereof
WO2014102299A2 (en) 2012-12-27 2014-07-03 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
BR112015020315A2 (pt) 2013-03-11 2017-10-10 Genzyme Corp conjugação de anticorpo-fármaco sítio-específica por glicoengenharia
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
KR102090356B1 (ko) * 2013-03-15 2020-03-18 메모리얼 슬로안 케터링 캔서 센터 다량체화 기술
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
WO2014151910A1 (en) * 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
RU2015141529A (ru) * 2013-04-05 2017-05-15 Дженентек, Инк. Антитела и биспецифические антитела к il-4 и их применение
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3055329B1 (de) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispezifische antikörper mit domänengetauschten, gemeinsamen, variablen leichten ketten
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR102597804B1 (ko) * 2013-12-20 2023-11-07 제넨테크, 인크. 이중 특이적 항체
EP2893939A1 (de) 2014-01-10 2015-07-15 Netris Pharma Anti-Netrin-1-Antikörper
US20150225479A1 (en) * 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
EP3107574A2 (de) * 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anti-il-13/il-17 bispezifische antikörper und verwendungen davon
DK3129067T5 (da) 2014-03-19 2024-10-14 Genzyme Corp Sitespecifik glycomodificering af målsøgningsdele
CA2942697A1 (en) 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
TWI745962B (zh) 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法
EA201790173A1 (ru) 2014-07-11 2017-06-30 Генмаб А/С Антитела, связывающие axl
WO2016044707A1 (en) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
US10064952B2 (en) 2014-10-09 2018-09-04 Genzyme Corporation Glycoengineered antibody drug conjugates
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP6686897B2 (ja) * 2014-11-21 2020-04-22 アステラス製薬株式会社 新規二重特異的抗体フォーマット
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3247725B1 (de) 2015-01-23 2020-07-01 Sanofi Anti-cd3-antikörper, anti-cd123-antikörper und bispezifische, spezifisch an cd3 und/oder cd123 bindende antikörper
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3067062A1 (de) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Kombination von tasquinimod oder einem pharmazeutisch zulässigen salz davon und pd1 und/oder pdl1-hemmer zur verwendung als medikament
AU2016233398A1 (en) * 2015-03-16 2017-09-07 F. Hoffmann-La Roche Ag Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3730520A1 (de) 2015-07-10 2020-10-28 Genmab A/S Axl-spezifische antikörper-wirkstoff-konjugate zur krebsbehandlung
EP3819310A1 (de) 2015-10-25 2021-05-12 Sanofi Trispezifische und/oder trivalente bindungsproteine zur prävention oder behandlung von hiv-infektion
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
JP7078536B2 (ja) 2016-01-08 2022-05-31 アルトゥルバイオ， インコーポレイテッド 四価抗ｐｓｇｌ－１抗体とその使用
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
HRP20231188T1 (hr) 2016-04-13 2024-02-02 Sanofi Trispecifični i/ili trovalentni vezujući proteini
SG11201808911SA (en) 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins
US11390669B2 (en) 2016-04-27 2022-07-19 Abbvie, Inc. Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
CN117247458A (zh) 2016-07-14 2023-12-19 健玛保 针对cd40和cd137的多特异性抗体
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
HRP20240474T1 (hr) 2016-08-26 2024-07-05 Sanofi Multispecifična protutijela koja olakšavaju selektivno uparivanje lakog lanca
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
KR20190070977A (ko) 2016-11-01 2019-06-21 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN110291105B (zh) 2017-01-05 2024-03-01 奈特里斯药物公司 导蛋白-1干扰药物和免疫检查点抑制剂药物的组合治疗
JP7304288B2 (ja) * 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR101961871B1 (ko) * 2017-02-20 2019-07-17 주식회사 와이바이오로직스 신규 다중특이적 결합 단백질
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
KR20200027944A (ko) 2017-06-07 2020-03-13 젠맵 비. 브이 돌연변이된 igg 육량체에 기초한 치료 항체
CN111108120A (zh) * 2017-07-03 2020-05-05 财团法人生物技术开发中心 抗人类血管内皮生长因子受体的抗体及其应用
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
CN117964758A (zh) 2017-10-10 2024-05-03 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CN109705217B (zh) * 2017-10-25 2020-09-11 北京智仁美博生物科技有限公司 抗il-13抗体及其用途
CN111526920A (zh) 2017-10-30 2020-08-11 赛诺菲生物技术公司 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
BR112020013325A2 (pt) 2018-01-12 2020-12-01 Genzyme Corporation métodos para quantificação de polipeptídeos
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
WO2019147973A1 (en) 2018-01-26 2019-08-01 Genzyme Corporation Fc variants with enhanced binding to fcrn and prolonged half-life
US20210024632A1 (en) * 2018-03-05 2021-01-28 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
CN112040953A (zh) * 2018-03-09 2020-12-04 布赖汉姆妇女医院 用于心血管疾病的组合治疗
WO2019211472A1 (en) 2018-05-03 2019-11-07 Genmab B.V. Antibody variant combinations and uses thereof
EP3574915A1 (de) 2018-05-29 2019-12-04 Neovacs Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
MX2020013631A (es) 2018-07-13 2021-03-25 Genmab As Variantes de anticuerpo grupo de diferenciacion (cd38) y usos de las mismas.
WO2020012038A1 (en) 2018-07-13 2020-01-16 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
MX2021003756A (es) 2018-10-04 2021-08-11 Genmab Holding B V Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
SG11202103478RA (en) 2018-10-09 2021-05-28 Sanofi Sa Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
KR102330596B1 (ko) * 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP2022515188A (ja) 2018-12-21 2022-02-17 エイム・イムノテック・インコーポレイテッド がん治療のための組成物および方法
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
WO2020180727A1 (en) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CA3141492A1 (en) 2019-05-24 2020-12-03 Sanofi Methods for treating systemic sclerosis
EP3753954A1 (de) 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123-antikörper, chimäre anti-cd123-antigen-rezeptoren und chimäre anti-cd123-antigen-rezeptoren-t-zellen
EP3999532A2 (de) 2019-07-16 2022-05-25 Sanofi Neutralisierung von anti-amyloid-beta-antikörpern zur behandlung von morbus alzheimer
JP2022542884A (ja) 2019-07-25 2022-10-07 ジェンザイム・コーポレーション Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021144020A1 (en) 2020-01-15 2021-07-22 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2021152175A1 (en) 2020-01-31 2021-08-05 Sanofi Pulmonary delivery of antibodies
EP4110404A1 (de) 2020-02-28 2023-01-04 Genzyme Corporation Modifizierte bindende polypeptide zur optimierten wirkstoffkonjugation
CN115209881A (zh) 2020-03-03 2022-10-18 活跃生物技术有限公司 用于组合疗法的他喹莫德或其药学上可接受的盐
TW202146463A (zh) 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
CR20220521A (es) 2020-03-18 2023-01-23 Genmab As Anticuerpos
US20230181755A1 (en) 2020-04-24 2023-06-15 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
TW202206109A (zh) 2020-04-24 2022-02-16 法商賽諾菲公司 含有抗ｃｅａｃａｍ５抗體接合物與ｆｏｌｆｉｒｉ之抗腫瘤組合
TW202203981A (zh) 2020-04-24 2022-02-01 法商賽諾菲公司 含有抗ｃｅａｃａｍ５抗體接合物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）的抗腫瘤組合
CN115427082A (zh) 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
CN114957472B (zh) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
WO2021263075A1 (en) * 2020-06-26 2021-12-30 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
EP4185388A1 (de) 2020-07-23 2023-05-31 Genmab B.V. Kombination aus anti-dr5-antikörpern und einem immunmodulatorischen imidwirkstoff zur verwendung bei der behandlung von multiplem myelom
BR112023003868A2 (pt) 2020-09-02 2023-04-04 Genmab As Método para prevenir ou reduzir o crescimento de um tumor, agente de ligação para uso em prevenir ou reduzir o crescimento de tumor, composição imunogênica compreendendo pelo menos um antígeno de vacina para uso, usos de um agente de ligação e de uma composição imunogênica, e, kit de partes compreendendo um agente de ligação
CN116113439A (zh) 2020-09-04 2023-05-12 默克专利股份公司 抗ceacam5抗体和缀合物及其用途
AR125581A1 (es) * 2020-12-07 2023-08-02 UCB Biopharma SRL Anticuerpos multiespecíficos y combinaciones de anticuerpos
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
AR125815A1 (es) 2021-05-07 2023-08-16 Genmab As Composiciones farmacéuticas que comprenden anticuerpos biespecíficos que se unen a b7h4 y cd3
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
CA3225636A1 (en) 2021-07-02 2023-01-05 Merck Patent Gmbh Anti-protac antibodies and complexes
WO2023021195A1 (en) * 2021-08-20 2023-02-23 Neovacs mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF
IL312519A (en) 2021-11-05 2024-07-01 Lilly Co Eli Anticancer combinations containing antibody-drug conjugates anti-CEACAM5 and anti-VEGFR-2 antibodies
CA3241374A1 (en) 2021-12-30 2023-07-06 Gregory GEBA Methods for attenuating atopic march by administering an il-4/il-13 antagonist
IL315262A (en) * 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
WO2023170240A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
EP4245772A1 (de) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1-antikörper zur behandlung von leberentzündung
EP4249509A1 (de) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1-antikörper gegen arthritis-assoziierte schmerzen
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
TW202432574A (zh) 2022-10-25 2024-08-16 比利時商艾伯霖克斯公司 具有增強的效應子功能之糖基工程化Ｆｃ變體多肽
WO2024141496A1 (en) 2022-12-27 2024-07-04 Merck Patent Gmbh Vhh anti-protac antibodies and complexes
EP4413995A1 (de) 2023-02-07 2024-08-14 Université de Franche-Comté Chimäre anti-cd123-antigen-rezeptoren-t-zellen zur verwendung bei der behandlung von autoimmunerkrankungen
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
WO2024180192A1 (en) 2023-03-01 2024-09-06 Sanofi Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (de) 2023-03-06 2024-09-11 Sanofi Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-vegfr-2-antikörpern und anti-pd1/pd-l1-antikörpern
WO2024194455A1 (en) 2023-03-23 2024-09-26 Sanofi CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
EP4434586A1 (de) 2023-03-23 2024-09-25 Xenothera Kombination von antikörpern oder antigenbindenden fragmenten davon zur behandlung von krebs und zusammensetzung davon

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (de) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotikum C-15003 PHO und seine Herstellung
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (de) 1985-04-01 1995-04-26 Celltech Limited Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
ATE119198T1 (de) 1988-04-16 1995-03-15 Celltech Ltd Verfahren zur herstellung von proteinen mittels rekombinanter dna.
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
CA2018228C (en) 1989-06-05 1996-02-27 Nancy L. Parenteau Cell culture systems and media
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2078689C (en) 1990-03-20 2003-02-11 Sherie L. Morrison Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2178635T3 (es) 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
WO1993025788A1 (en) 1992-06-09 1993-12-23 Hoppe Ag Latch and lockset system
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
AU695726B2 (en) 1993-09-07 1998-08-20 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
ZA946875B (en) * 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5597710A (en) 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0822830B1 (de) 1995-04-27 2008-04-02 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997014719A1 (en) * 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
DE69731289D1 (de) 1996-03-18 2004-11-25 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
WO1997034911A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP2305027B1 (de) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgene Saügertiere, die menschlichen Ig-loci einschließlich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
HU221818B1 (hu) 1997-04-14 2003-01-28 Micromet Ag Új eljárás humán antigén elleni receptorok előállítására, és azok alkalmazása
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6994853B1 (en) 1998-09-25 2006-02-07 Trion Pharma Gmbh Time-staggered utilization of tumor cells in combination with intact antibodies for immunization
KR20130105766A (ko) * 1999-03-25 2013-09-25 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
JP2004511430A (ja) * 2000-05-24 2004-04-15 イムクローン　システムズ　インコーポレイティド 二重特異性免疫グロブリン様抗原結合蛋白および製造方法
JP2004523205A (ja) * 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
RU2295537C2 (ru) * 2000-10-20 2007-03-20 Тугаи Сейяку Кабусики Кайся Модифицированное агонистическое антитело
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
US20040023337A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US6811780B2 (en) 2002-05-01 2004-11-02 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
JP2006526408A (ja) 2003-04-22 2006-11-24 アイビーシー、ファーマシューティカルズ 多価タンパク質複合体
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI356064B (en) * 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
PL1703893T3 (pl) * 2003-12-23 2012-09-28 Genentech Inc Nowe przeciwciała anty-IL 13 i ich zastosowania
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
CN1922490B (zh) * 2004-02-19 2012-07-04 耶鲁大学 使用蛋白质组学技术鉴定癌症蛋白生物标志物的方法
WO2005085284A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 sepecific polypetides and therapeutic uses thereof
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
AU2005248400A1 (en) * 2004-05-25 2005-12-08 Attenuon, Llc Ligands binding the complex of urokinase-type plasminogen activator (uPa) and its receptor (uPAR) that inhibit downstream upar interactions: identification and use in diagnosis or therapy
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
GB0514319D0 (en) * 2005-07-13 2006-06-14 Secr Defence Antibodies for anthrax
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SI1942939T2 (sl) 2005-09-30 2021-11-30 Medimmune Limited Sestavek protitelesa proti interlevkinu-13
WO2007045477A2 (en) * 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
EA200801515A1 (ru) 2006-01-24 2009-02-27 Домантис Лимитед Лиганды, которые связывают il-4 и/или il-13
EP2004691A1 (de) 2006-03-22 2008-12-24 Apogenix GmbH Für humanes il-4 spezifischer antikörper zur behandlung von krebs
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JP2014510730A (ja) * 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TWI745962B (zh) * 2014-06-27 2021-11-11 法商賽諾菲公司 測定投予至人類個體之包括雙-v-區類抗體蛋白或其片段的劑量是否在人類個體中與il-4或il-13特異性結合之方法

Also Published As

Publication number Publication date
NI201000040A (es) 2010-09-07
NZ584658A (en) 2012-08-31
US20130243778A1 (en) 2013-09-19
HRP20180517T1 (hr) 2018-05-04
TR201810005T4 (tr) 2018-08-27
JP5858616B2 (ja) 2016-02-10
US20130236462A1 (en) 2013-09-12
US20130209469A1 (en) 2013-08-15
CY1119875T1 (el) 2018-06-27
CY1120108T1 (el) 2018-12-12
PL2574630T3 (pl) 2018-09-28
AU2013203339B9 (en) 2017-02-02
AU2013203324A1 (en) 2013-05-02
CY1120887T1 (el) 2019-12-11
DK2205640T3 (en) 2014-02-24
TN2010000126A1 (en) 2011-09-26
NI201000402A (es) 2010-09-07
HRP20140150T1 (hr) 2014-03-28
HRP20181085T1 (hr) 2018-09-07
AU2008312655B2 (en) 2013-05-02
PE20091382A1 (es) 2009-10-14
JP6280526B2 (ja) 2018-02-14
EP2574626A1 (de) 2013-04-03
SI2573121T1 (en) 2018-01-31
PT2573121T (pt) 2017-11-21
NO2574629T3 (de) 2018-04-21
US20130243777A1 (en) 2013-09-19
KR20180014189A (ko) 2018-02-07
GT201000067A (es) 2012-04-12
ES2647872T3 (es) 2017-12-27
RS56914B1 (sr) 2018-05-31
US20100226923A1 (en) 2010-09-09
KR101681909B1 (ko) 2016-12-05
CY1114987T1 (el) 2016-12-14
ES2447915T3 (es) 2014-03-13
KR20100067669A (ko) 2010-06-21
PA8799001A1 (es) 2009-07-23
AR068861A1 (es) 2009-12-09
CA3071750C (en) 2022-06-14
SG10201913838RA (en) 2020-03-30
AR122833A2 (es) 2022-10-12
US8388965B2 (en) 2013-03-05
US20130259866A1 (en) 2013-10-03
EP2573119B1 (de) 2018-01-03
EP2050764A1 (de) 2009-04-22
NI201000405A (es) 2010-09-07
CL2012003196A1 (es) 2013-01-25
RU2580049C2 (ru) 2016-04-10
BRPI0818677B1 (pt) 2019-11-12
US11453727B2 (en) 2022-09-27
PH12013501033B1 (en) 2015-05-25
RU2721236C2 (ru) 2020-05-18
WO2009052081A3 (en) 2009-06-04
PT2574629T (pt) 2018-02-23
RS53175B (en) 2014-06-30
CN113480647A (zh) 2021-10-08
DK2574630T3 (en) 2018-07-30
CA3071750A1 (en) 2009-04-23
CN106986938A (zh) 2017-07-28
RS57396B1 (sr) 2018-09-28
RU2013120318A (ru) 2014-11-10
JP2015231382A (ja) 2015-12-24
CN106986938B (zh) 2021-07-09
NI201000401A (es) 2010-09-07
HUE038444T2 (hu) 2018-10-29
ES2664476T3 (es) 2018-04-19
EP2205640B1 (de) 2013-11-20
ES2679281T3 (es) 2018-08-23
KR101823859B1 (ko) 2018-02-01
CR11337A (es) 2010-04-21
US20230235088A1 (en) 2023-07-27
HN2010000710A (es) 2013-07-22
CY1120033T1 (el) 2018-12-12
PH12013501032B1 (en) 2015-05-18
DOP2013000302A (es) 2014-02-16
SI2573119T1 (en) 2018-05-31
CA2702473A1 (en) 2009-04-23
CN101827863A (zh) 2010-09-08
RU2015141428A (ru) 2017-04-04
IL205005A0 (en) 2010-11-30
MX354666B (es) 2018-03-15
EP2573119A1 (de) 2013-03-27
CR20150103A (es) 2015-04-14
BRPI0818677B8 (pt) 2021-05-25
CR20150102A (es) 2015-04-30
PT2574630T (pt) 2018-07-17
SG185303A1 (en) 2012-11-29
SG10201913836SA (en) 2020-03-30
AU2013203339A1 (en) 2013-05-02
PH12013501032A1 (en) 2015-05-18
RU2015141428A3 (de) 2019-04-30
BRPI0818677A2 (pt) 2015-04-14
EP2574630B1 (de) 2018-04-18
KR101682373B1 (ko) 2016-12-06
EP2574629B1 (de) 2017-11-22
IL249289A0 (en) 2017-01-31
HUE036530T2 (hu) 2018-07-30
CA3015470C (en) 2022-01-18
PL2205640T3 (pl) 2014-05-30
IL205005A (en) 2016-11-30
LT2574630T (lt) 2018-07-25
NZ729148A (en) 2021-12-24
EP2573115A1 (de) 2013-03-27
RU2015141418A3 (de) 2019-05-14
TW200932263A (en) 2009-08-01
AU2013203339B2 (en) 2017-01-05
JP6126653B2 (ja) 2017-05-10
TWI616205B (zh) 2018-03-01
US20130251716A1 (en) 2013-09-26
RS57060B1 (sr) 2018-05-31
CN101827863B (zh) 2017-03-22
TW201825117A (zh) 2018-07-16
HRP20171765T1 (hr) 2017-12-29
US20130236460A1 (en) 2013-09-12
CL2013002040A1 (es) 2014-01-24
AU2013202389B9 (en) 2017-02-02
CA2702473C (en) 2018-10-09
TWI616206B (zh) 2018-03-01
AU2013202389B2 (en) 2017-01-05
US20130236461A1 (en) 2013-09-12
AU2013203328A1 (en) 2013-05-02
TW201536322A (zh) 2015-10-01
MX363634B (es) 2019-03-28
HUE038556T2 (hu) 2018-10-29
MX363901B (es) 2019-04-08
EP2574630A1 (de) 2013-04-03
PT2205640E (pt) 2014-02-25
DK2574629T3 (en) 2018-02-26
US20130236463A1 (en) 2013-09-12
AU2013203328B9 (en) 2017-02-02
US20210047437A1 (en) 2021-02-18
NI201000403A (es) 2010-09-07
LT2573119T (lt) 2018-04-10
US20180030156A1 (en) 2018-02-01
MX363638B (es) 2019-03-28
RU2705551C2 (ru) 2019-11-07
CR20150101A (es) 2015-04-14
RU2010119521A (ru) 2011-11-27
DOP2013000301A (es) 2014-02-16
UA118949C2 (uk) 2019-04-10
PH12013501033A1 (en) 2015-05-25
JP2018078907A (ja) 2018-05-24
EP2573121A1 (de) 2013-03-27
KR20190022928A (ko) 2019-03-06
EP2205640A2 (de) 2010-07-14
SI2205640T1 (sl) 2014-04-30
CL2008003037A1 (es) 2009-03-06
AU2013203324C1 (en) 2017-03-30
WO2009052081A2 (en) 2009-04-23
EP2573116A1 (de) 2013-03-27
UY31394A1 (es) 2009-05-29
NI201000404A (es) 2010-09-07
KR20140112574A (ko) 2014-09-23
MY171214A (en) 2019-10-02
JP6126652B2 (ja) 2017-05-10
RU2015141418A (ru) 2017-04-04
EP2573121B1 (de) 2017-08-23
US9732162B2 (en) 2017-08-15
US9738728B2 (en) 2017-08-22
MA31838B1 (fr) 2010-11-01
CL2013002039A1 (es) 2014-03-07
LT2573121T (lt) 2017-12-11
WO2009052081A4 (en) 2009-07-23
NZ601342A (en) 2014-02-28
EP2574629A1 (de) 2013-04-03
NI201000406A (es) 2010-09-07
LT2574629T (lt) 2018-03-12
US20130251717A1 (en) 2013-09-26
HUE037205T2 (hu) 2018-08-28
DK2573119T3 (en) 2018-04-16
PL2573121T3 (pl) 2018-01-31
SI2574630T1 (en) 2018-08-31
US20140023649A1 (en) 2014-01-23
AU2013203328B2 (en) 2017-01-05
ZA201002069B (en) 2010-12-29
AR122834A2 (es) 2022-10-12
SI2574629T1 (en) 2018-03-30
TW201536321A (zh) 2015-10-01
CA3015470A1 (en) 2009-04-23
AU2013203324B2 (en) 2017-01-19
DOP2010000109A (es) 2010-05-31
HRP20180320T1 (hr) 2018-04-06
DK2573121T3 (en) 2017-12-04
PT2573119T (pt) 2018-04-04
SG10201602770UA (en) 2016-05-30
EP2573118A1 (de) 2013-03-27
US10759871B2 (en) 2020-09-01
KR20160142889A (ko) 2016-12-13
JP2016006086A (ja) 2016-01-14
US20130251718A1 (en) 2013-09-26
RS56553B1 (sr) 2018-02-28
KR101954596B1 (ko) 2019-03-07
AU2013202389A1 (en) 2013-05-02
JP2016006087A (ja) 2016-01-14
NZ709353A (en) 2018-06-29
MX354150B (es) 2018-02-15
MX2010003290A (es) 2010-04-30
PL2573119T3 (pl) 2018-07-31
JP2011501671A (ja) 2011-01-13
AU2008312655A1 (en) 2009-04-23
TWI619508B (zh) 2018-04-01
CR20150654A (es) 2016-02-08
RU2488595C2 (ru) 2013-07-27
ES2660152T3 (es) 2018-03-21
PL2574629T3 (pl) 2018-05-30
TR201802225T4 (tr) 2018-03-21
US20130243776A1 (en) 2013-09-19
EP2573117A1 (de) 2013-03-27
EP3686220A1 (de) 2020-07-29
UA104130C2 (uk) 2014-01-10

Similar Documents

Publication Publication Date Title
CN300726264S (zh) 墙纸(24a)
CN300726484S (zh) 博古架(hd4006)
CN300726579S (zh) 枕套(零度贵魅)
CN300726617S (zh) 茶壶(02)
CN300726704S (zh) 牙签筒(5)
CN300727217S (zh) 多功能电子计步器
CN300727291S (zh) 工艺品(champion系列——一跃龙门)
CN300727312S (zh) 考拉警车(eg6043k)
CN300727315S (zh) 汽车(ga6461)
CN300727316S (zh) 汽车(ga6490ct)
CN300727343S (zh) 摩托车仪表支架
CN300727517S (zh) 移动插座(kl04-08)
CN300727540S (zh) 玛瑙开关(双按钮ⅰ)
CN300727620S (zh) USB存储器(Freeezer-Big Red)
CN300727673S (zh) 电话机(3618)
CN300727760S (zh) 制冰机(ⅲ)
CN300727767S (zh) 电冰箱控制面板(2)
CN300727810S (zh) 竖笛(8)
CN300728011S (zh) 电梯用液晶显示器
CN300728065S (zh) 太阳能飞行器
CN300728240S (zh) 分体挂壁式空调器(一)
CN300728344S (zh) 电动门(龙腾1号)
CN300728490S (zh) 宠物屋
CN300728506S (zh) 冰淇淋机(icm-4)
CN300728620S (zh) 鞋底